Relypsa

AstraZeneca global RD HQ

Marketing

AZ finally wins hard-fought FDA nod for ZS-9, now dubbed Lokelma

Lokelma moved past two rejections to win its nod, and now it's ready to tackle Vifor's hyperkalemia rival Veltassa, approved back in 2015.

Angus Liu May 21, 2018 11:10am

Veltassa

Galenica snaps up Relypsa for $1.53B in march toward Vifor spinoff

Jul 21, 2016 8:06am

Veltassa

Relypsa's Veltassa launch gets a leg up from AZ's ZS-9 setback

Jun 1, 2016 7:03am

ZS Pharma

Buyers eye Relypsa and its hyperkalemia drug

Apr 8, 2016 9:59am